Rosiglitazone: safety, efficacy and influence on cardiovascular outcomes in patients with type 2 diabetes mellitus.
The last 10 years were marked by the introduction of thiazolidinediones in the practice of diabetic treatment; their main therapeutic effects are associated with increased sensitivity of peripheral tissues to insulin and increased absorption of glucose by peripheral tissues leading to reduction of glucose blood level. We review the results of three long-term randomized trials - ADOPT, DREAM and RECORD, devoted to the study of efficacy and safety of rosiglitazone (Avandia) in diabetes mellitus treatment, as well as analysis of cardiovascular complications and indicators of cardiovascular mortality during therapy. These data suggest that rosiglitazone remains an important antidiabetic drug, subject to his administration for cause.

Keywords: thiazolidinediones, vascular complications of diabetes, type 2diabetes mellitus, rosiglitazone